Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Senti Bio initiated with a Buy at BofA » 06:53
09/29/22
09/29
06:53
09/29/22
06:53
SNTI

Senti Bio

$1.41 /

+0.17 (+13.71%)

BofA analyst Greg…

BofA analyst Greg Harrison initiated coverage of Senti Bio with a Buy rating and $7 price target. Senti's gene circuit platform is "differentiated" and offers potential to attack new cancer targets with fewer on-target off-tumor effects compared to current approaches, Harrison tells investors in a research note. The analyst sees significant unmet need in the initial targeted indications of acute myeloid leukemia and hepatocellular carcinoma and thinks peak unadjusted revenues greater than $1B in 2031.

ShowHide Related Items >><<
SNTI Senti Bio
$1.41 /

+0.17 (+13.71%)

SNTI Senti Bio
$1.41 /

+0.17 (+13.71%)

09/22/22 Chardan
Senti Bio initiated with a Buy at Chardan
Over a week ago
Initiation
Senti Bio initiated with a Buy at Chardan » 16:07
09/22/22
09/22
16:07
09/22/22
16:07
SNTI

Senti Bio

$1.40 /

-0.14 (-9.09%)

Chardan analyst Geulah…

Chardan analyst Geulah Livshits initiated coverage of Senti Bio with a Buy rating and $12 price target. The rating reflects the analyst view on the potential of Senti's gene circuit synthetic biology platform and engineered cell therapy pipeline, which she thinks may be able to address several limitations of current cell and gene therapy modalities. Proof of concept can lay the foundations for future programs and the company has collaborations with Roche/Spark on synthetic cell type-specific promoters for gene therapies and with Bayer/BlueRock beyond its internal pipeline, Livshits noted.

ShowHide Related Items >><<
SNTI Senti Bio
$1.40 /

-0.14 (-9.09%)

Syndicate
Senti Bio files to sell 8.73M shares of common stock for holders  17:15
09/12/22
09/12
17:15
09/12/22
17:15
SNTI

Senti Bio

$2.24 /

+0.155 (+7.43%)

 
ShowHide Related Items >><<
SNTI Senti Bio
$2.24 /

+0.155 (+7.43%)

Over a quarter ago
Syndicate
Senti Bio files to sell 2M shares of common stock  16:31
06/28/22
06/28
16:31
06/28/22
16:31
SNTI

Senti Bio

$2.08 /

-0.09 (-4.15%)

 
ShowHide Related Items >><<
SNTI Senti Bio
$2.08 /

-0.09 (-4.15%)

Syndicate
Senti Bio files to sell 33.44M shares of common stock for holders  16:31
06/28/22
06/28
16:31
06/28/22
16:31
SNTI

Senti Bio

$2.08 /

-0.09 (-4.15%)

 
ShowHide Related Items >><<
SNTI Senti Bio
$2.08 /

-0.09 (-4.15%)

Hot Stocks
Senti Biosciences Inc trading resumes  10:13
06/10/22
06/10
10:13
06/10/22
10:13
SNTI

Senti Bio

$6.70 /

+0.38 (+6.01%)

 
ShowHide Related Items >><<
SNTI Senti Bio
$6.70 /

+0.38 (+6.01%)

Hot Stocks
Senti Biosciences Inc trading halted, volatility trading pause  10:03
06/10/22
06/10
10:03
06/10/22
10:03
SNTI

Senti Bio

$6.79 /

+0.47 (+7.44%)

 
ShowHide Related Items >><<
SNTI Senti Bio
$6.79 /

+0.47 (+7.44%)

Hot Stocks
Senti Bio debuts as publicly traded company on Nasdaq Global Market » 07:50
06/09/22
06/09
07:50
06/09/22
07:50
SNTB

Senti Bio

/

+

, SNTI

Senti Bio

$7.52 /

-0.46 (-5.76%)

, DYNS

Dynamics Special Purpose

/

+

Senti Biosciences…

Senti Biosciences announced the completion of its business combination with Dynamics Special Purpose Corp., a special purpose acquisition company. Senti Biosciences, Inc., the resulting combined company, will commence trading on the Nasdaq Global Market under the symbol "SNTI" on June 9, 2022. Senti Bio is developing next-generation cell and gene therapies engineered with gene circuits, which are designed to reprogram cells with biological logic to sense inputs, compute decisions and respond to their respective cellular environments. Senti Bio's oncology pipeline uses healthy adult donor-derived, natural killer cells engineered with chimeric antigen receptor gene circuits that are cryopreserved and dosed off-the-shelf. Senti Bio's oncology pipeline is primarily focused on three preclinical-stage programs: SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia cells while sparing the healthy bone marrow; SENTI-301, a regulatable Multi-Armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma; and SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer cells while sparing healthy cells elsewhere in the body. In addition, the company is collaborating with Spark Therapeutics and BlueRock Therapeutics on applications of its gene circuit technology outside of oncology. Senti Bio received gross proceeds of approximately $140.3 million of the expected $156.5 million in connection with the business combination, which included funds held in DYNS's trust account of $84.5 million, $50.6 million of the expected $66.8 million in proceeds from a private investment in public equity financing that closed concurrently with the consummation of the business combination, and a recent $5.2 million investment by Leaps by Bayer, the impact investment arm of Bayer AG, through the purchase of a convertible note that was exchanged at the closing of the business combination for common equity with the same rights as the PIPE shares. Senti Bio expects the proceeds from this transaction, combined with cash on hand, to fund operations into 2024. Investors in DYNS include funds managed by ARK Investment Management LLC, funds and accounts managed by Counterpoint Global, Invus, and funds and accounts advised by T. Rowe Price Associates, Inc., among others. Investors participating in the PIPE financing as of the closing of the business combination included 8VC, Amgen Ventures, funds and accounts managed by Counterpoint Global, Invus, NEA, Parker Institute for Cancer Immunotherapy, and T. Rowe Price funds, among others. Of the $66.8 million in subscriptions for the PIPE financing, $16.2 million has yet to be funded as one investor, who entered into a subscription agreement concurrently with Senti Bio and DYNS's execution of the business combination agreement in December 2021, has not funded its commitment. Senti Bio intends to enforce such one investor's legal obligations under its subscription agreement. Solely for purposes of consummating the business combination on June 8, 2022, Senti Bio agreed to waive the $150 million available cash closing condition under the business combination agreement previously entered into with DYNS. DYNS's board members, Dr. Omid Farokhzad and David Epstein, have joined the Senti Bio Board of Directors. The other Senti Bio board members are Susan Berland, Dr. James Collins, Dr. Brenda Cooperstone, Dr. Timothy Lu and Edward Mathers. Proceeds from the transaction are expected to provide Senti Bio with capital to further develop its gene circuit technologies and therapeutic pipeline, including: Conducting Investigational New Drug- enabling studies for SENTI-202 and SENTI-301; Building out clinical-scale current good manufacturing practice capabilities and enabling cGMP runs for off-the-shelf CAR-NK cell therapies; Alameda, CA, facility startup on track for year-end 2022; Filing IND applications for SENTI-202 and SENTI-301 in 2023; Advancing SENTI-202 and SENTI-301 toward Phase 1/2 dose escalation clinical trials; Advancing its gene circuit platform with additional programs, such as SENTI-401 towards an anticipated IND filing in 2024, for solid tumors; Building out its gene circuit platform to expand modalities and therapeutic areas through potential collaborations and/or partnerships.

ShowHide Related Items >><<
SNTB Senti Bio
/

+

DYNS Dynamics Special Purpose
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.